6 extractive question-and-answer pairs built from 1725952329 pulmonology asthma, published by icmr.gov.in. Every answer is a verbatim span of text the source prints, and each row carries the passage it sits in, its offset in that passage, the source quote, the page and the location in the document, so any row can be checked against the original. 5 of the 6 pairs (83.3%) are explanatory questions and 1 restate a figure. 100.00% of rows pass the corpus quality gate.
Use the API URL with your free DD token in notebooks, scripts, and pipelines.
https://www.desidata.in/api/datasets/pulmonology-and-asthma-question-and-answer-dataset/downloadDataset downloads are free. For Python or API downloads, sign in once and create a free DD token; set it as DD_TOKEN or save it in your notebook's secrets. Requests are linked to your account so your download history and counts stay accurate.
# One-time install: pip install desidata
# Set DD_TOKEN in your environment first (create a free token in Profile & settings).
import desidata
df = desidata.load("pulmonology-and-asthma-question-and-answer-dataset")
df.head()Sign in with Google to download.
Usable for analysis, but expect some cleaning before you rely on it.
Consensus Document on Management of Pancreatic Cancer - Question and Answer Dataset
Economy · 268 rows
ICMR Standard Treatment Workflow for Cataract - Question and Answer Dataset
Economy · 27 rows
Neurology Questions from P a R T N E R S - Question and Answer Dataset
Economy · 107 rows
Beginner's Guide for Systematic Reviews - Question and Answer Dataset
Economy · 407 rows
Annual Report 2015-16 by agriwelfare.gov.in - Question and Answer Dataset
Economy · 1,013 rows
Higher Education in India - Question and Answer Dataset
Economy · 1,594 rows
Gender Policy of NABARD - Question and Answer Dataset
Economy · 14 rows
ICAR Annual Report 2025-26 - Question and Answer Dataset
Economy · 1,101 rows
First 6 of 6 rows
| question | answer | context | answer_start | question_type | knowledge_quality_score | source_quote | source_page | source_location | confidence | validation_status |
|---|---|---|---|---|---|---|---|---|---|---|
| What is the full form of FEV1? | Forced Expiratory Volume in first second | Components Inadequately controlled (any one) Adequately controlled (all should be present) Daytime symptoms or use of rescue medication More than twice a week Twice or less in a week Night-time symptoms/ awakening Any Any None None Limitation of activities Pulmonary function (if available) FEV1 <80% of predicted or PEF <80% of personal best FEV1 >80% of predicted or PEF >80% of personal best FEV1 Forced Expiratory Volume in first second, PEF Peak Expiratory Flow | 400 | definition | 0.980 | Components Inadequately controlled (any one) Adequately controlled (all should be present) Daytime symptoms or use of rescue medication More than twice a week Twice or less in a week Night-time symptoms/ awakening Any Any None None Limitation of activities Pulmonary function (if available) FEV1 <80% of predicted or PEF <80% of personal best FEV1 >80% of predicted or PEF >80% of personal best FEV1 Forced Expiratory Volume in first second, PEF Peak Expiratory Flow | 1 | page=1,block=16 | 0.700 | valid |
| What is the full form of PEF? | Peak Expiratory Flow | Components Inadequately controlled (any one) Adequately controlled (all should be present) Daytime symptoms or use of rescue medication More than twice a week Twice or less in a week Night-time symptoms/ awakening Any Any None None Limitation of activities Pulmonary function (if available) FEV1 <80% of predicted or PEF <80% of personal best FEV1 >80% of predicted or PEF >80% of personal best FEV1 Forced Expiratory Volume in first second, PEF Peak Expiratory Flow | 446 | definition | 0.900 | Components Inadequately controlled (any one) Adequately controlled (all should be present) Daytime symptoms or use of rescue medication More than twice a week Twice or less in a week Night-time symptoms/ awakening Any Any None None Limitation of activities Pulmonary function (if available) FEV1 <80% of predicted or PEF <80% of personal best FEV1 >80% of predicted or PEF >80% of personal best FEV1 Forced Expiratory Volume in first second, PEF Peak Expiratory Flow | 1 | page=1,block=16 | 0.700 | valid |
| What are some signs or conditions that can resemble obstructive airway disorders? | presence of fever, constitutional symptoms, purulent sputum, hemoptysis, focal chest signs on physical examination, foreign body aspiration, abnormal chest radiograph, etc. | TRY AND RULE OUT • Other obstructive airway disorders – see Table 1 for features that favour asthma over COPD • Other mimics – presence of fever, constitutional symptoms, purulent sputum, hemoptysis, focal chest signs on physical examination, foreign body aspiration, abnormal chest radiograph, etc. | 127 | list | 0.820 | TRY AND RULE OUT • Other obstructive airway disorders – see Table 1 for features that favour asthma over COPD • Other mimics – presence of fever, constitutional symptoms, purulent sputum, hemoptysis, focal chest signs on physical examination, foreign body aspiration, abnormal chest radiograph, etc. | 1 | page=1,block=3 | 0.700 | valid |
| What features can help support an asthma diagnosis? | History of atopy, family history of asthma, presence of triggers, presence of rhonchi on chest auscultation • No alternative explanation for these symptoms | Classic symptoms • Recurrent/episodic wheezing • Breathlessness • Cough and/or chest tightness Supportive features • History of atopy, family history of asthma, presence of triggers, presence of rhonchi on chest auscultation • No alternative explanation for these symptoms GUIDING PRINCIPLES • Mainstay of pharmacotherapy: Inhaled drugs • Frequency of symptoms determine treatment initiation (see figure 1 for details) • Reassess at 3-4 weeks – good response : in favour of asthma diagnosis • Patient education for compliance, warning signs, triggers, inhaler technique, PEF monitoring • Inhaler technique to be monitored • Follow-up at 4-12 weeks, assess diseases control by clinical parameters (see Table 2) • Step-up or step-down treatment as per level of asthma control (see figure 1) • Follow up three-monthly and modulate treatment as needed • Refer for further evaluation and management if asthma remains poorly controlled WHEN TO SUSPECT EXACERBATION • Suspect if acute symptomatic worsening , or reduction in PEF to below 80% of personal best , while on continued treatment • Take two additional puffs of the inhaler used if symptoms persist, and repeat if needed • If no response after 24 hours, or symptomatic worsening, or further reduction in PEF, contact physician • Physician to assess severity of exacerbation and manage accordingly REFERENCES 1. | ||||||||
| What symptoms are typically associated with asthma? | Recurrent/episodic wheezing • Breathlessness • Cough and/or chest tightness | Classic symptoms • Recurrent/episodic wheezing • Breathlessness • Cough and/or chest tightness Supportive features • History of atopy, family history of asthma, presence of triggers, presence of rhonchi on chest auscultation • No alternative explanation for these symptoms GUIDING PRINCIPLES • Mainstay of pharmacotherapy: Inhaled drugs • Frequency of symptoms determine treatment initiation (see figure 1 for details) • Reassess at 3-4 weeks – good response : in favour of asthma diagnosis • Patient education for compliance, warning signs, triggers, inhaler technique, PEF monitoring • Inhaler technique to be monitored • Follow-up at 4-12 weeks, assess diseases control by clinical parameters (see Table 2) • Step-up or step-down treatment as per level of asthma control (see figure 1) • Follow up three-monthly and modulate treatment as needed • Refer for further evaluation and management if asthma remains poorly controlled WHEN TO SUSPECT EXACERBATION • Suspect if acute symptomatic worsening , or reduction in PEF to below 80% of personal best , while on continued treatment • Take two additional puffs of the inhaler used if symptoms persist, and repeat if needed • If no response after 24 hours, or symptomatic worsening, or further reduction in PEF, contact physician • Physician to assess severity of exacerbation and manage accordingly REFERENCES 1. | ||||||||
| What is the main approach used to diagnose the condition? | Clinical assessment is the mainstay | APPROACH TO DIAGNOSIS • Clinical assessment is the mainstay • Airway obstruction, and bronchodilator reversibility, on spirometry (if available) may support diagnosis • Refer patients for further work-up if diagnosis is in doubt | 24 | factual | 0.570 | APPROACH TO DIAGNOSIS • Clinical assessment is the mainstay • Airway obstruction, and bronchodilator reversibility, on spirometry (if available) may support diagnosis • Refer patients for further work-up if diagnosis is in doubt | 1 | page=1,block=12 | 0.700 | valid |
Read straight from the file — download or use the API URL for the full dataset.
| 117 |
| list |
| 0.820 |
| Classic symptoms • Recurrent/episodic wheezing • Breathlessness • Cough and/or chest tightness Supportive features • History of atopy, family history of asthma, presence of triggers, presence of rhonchi on chest auscultation • No alternative explanation for these symptoms GUIDING PRINCIPLES • Mainstay of pharmacotherapy: Inhaled drugs • Frequency of symptoms determine treatment initiation (see figure 1 for details) • Reassess at 3-4 weeks – good response : in favour of asthma diagnosis • Patient education for compliance, warning signs, triggers, inhaler technique, PEF monitoring • Inhaler |
| 1 |
| page=1,block=3 |
| 0.700 |
| valid |
| 19 |
| list |
| 0.780 |
| Classic symptoms • Recurrent/episodic wheezing • Breathlessness • Cough and/or chest tightness Supportive features • History of atopy, family history of asthma, presence of triggers, presence of rhonchi on chest auscultation • No alternative explanation for these symptoms GUIDING PRINCIPLES • Mainstay of pharmacotherapy: Inhaled drugs • Frequency of symptoms determine treatment initiation (see figure 1 for details) • Reassess at 3-4 weeks – good response : in favour of asthma diagnosis • Patient education for compliance, warning signs, triggers, inhaler technique, PEF monitoring • Inhaler |
| 1 |
| page=1,block=3 |
| 0.700 |
| valid |